• Explore /
  • Poster
  • / Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.

Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.

Abstract Video & Slides Poster

Authors

Charles Herbaux

Charles Herbaux

Centre Hospitalier Régional Universitaire de Lille, Institute of Hematolog-Tranfusion, Lille, France

Charles Herbaux , Olivier Casasnovas , Pierre Feugier , Gandhi Damaj , Reda Bouabdallah , Stephanie Guidez , Loic Ysebaert , Herve Tilly , Steven Le Gouill , Luc Fornecker , Nicolas Daguindau , Nadine Morineau , Corinne Haioun , Emmanuel Gyan , David Sibon , Rémy Gressin , Roch Houot , Gilles A. Salles , Franck Morschhauser , Guillaume Cartron

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT03276468

Citation

J Clin Oncol 38: 2020 (suppl; abstr 8053)

DOI

10.1200/JCO.2020.38.15_suppl.8053

Abstract #

8053

Poster Bd #

386

Abstract Disclosures

Similar Posters

First Author: Rajat Bannerji

First Author: Georg Lenz

First Author: Curtis Andrew Lachowiez

First Author: Nilanjan Ghosh